Biomarker Testing in Microinvasive Carcinoma of the Breast.

Am J Surg Pathol

Department of Pathology, Weill Cornell Medicine, New York, NY.

Published: November 2024

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000002252DOI Listing

Publication Analysis

Top Keywords

biomarker testing
4
testing microinvasive
4
microinvasive carcinoma
4
carcinoma breast
4
biomarker
1
microinvasive
1
carcinoma
1
breast
1

Similar Publications

PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG.

World J Urol

January 2025

Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, Room Be-304, 3015 GD, Rotterdam, The Netherlands.

Purpose: Up to 50% of high-risk non-muscle invasive bladder cancer (HR-NMIBC) patients fail Bacillus Calmette-Guérin (BCG) treatment, resulting in a high risk of progression and poor clinical outcomes. Biomarkers that predict outcomes after BCG are lacking. The antitumor effects of BCG are driven by a cytotoxic T cell response, which may be controlled by immune checkpoint proteins like Programmed Death Ligand 1 (PD-L1).

View Article and Find Full Text PDF

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

Afe Babalola University, Ado-Ekiti, Ekiti, Nigeria.

Background: Stress during pregnancy and postpartum periods has been associated with short-term cognitive deficits with potential long-term Alzheimer's disease (AD) risk. However, the biological mechanisms mediating these effects remain poorly understood. This study investigated the impacts of recurrent heat and simulated refugee camp stress across pregnancy and the postpartum period on cognition, affective behaviour, and AD neuropathological changes in primiparous rats.

View Article and Find Full Text PDF

Background: Non-coding RNA species, such as microRNA (miRNA), regulate multiple biological and pathological processes by binding to target mRNAs and facilitating alteration of translation levels via complexes such as RNA-induced silencing complex (RISC). Disrupting this process could contribute to AD pathogenesis by fostering aggregation of hyperphosphorylated microtubule-associated protein tau and amyloid-β (Aβ) peptides, and neuroinflammation. Understanding how these pathological changes are regulated remains our research focus.

View Article and Find Full Text PDF

Background: Autosomal dominant Alzheimer's Disease (ADAD) represents around 0.5% of all AD cases, and is caused by mutations in PSEN1, PSEN2 and APP genes. Gene expression studies can be useful for unravelling the physiopathology of AD and identifying potential biomarkers.

View Article and Find Full Text PDF

Background: New methods developed to estimate when AD biomarkers became abnormal in individuals have shown considerable heterogeneity in amyloid and tau pathology onset age. This work used polygenic scores (PGS) generated from CSF Aβ and ptau GWAS, individual-level genetic data, and estimated tau onset age (ETOA) to identify genetic influences on tau onset beyond APOE.

Method: Participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with genetic data, CSF biomarkers (Aβ and ptau), and longitudinal [F]Flortaucipir (FTP) tau PET were analyzed (N = 462).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!